Waterford, CT

The trials here

What the 3 trials at this site are about, from their registry records.

Conditions

• Diabetic eye disease3 trials
• Macular degeneration1 trial

Phase

• Phase 2/32 trials
• Phase 11 trial

Status

• Active, not recruiting2 trials
• Completed1 trial

Lead sponsor

• EyeBiotech Ltd.2 trials
• Ollin Biosciences, Inc.1 trial

Running trials

• Active, not recruiting

  A Study of 2 Doses of Remigromig (EYE103) Compared With Ranibizumab (0.5 mg) in Participants With DME

  NCT06957080· Phase 2/3· EyeBiotech Ltd.· Source

• Active, not recruiting

  A Study to Evaluate the Efficacy and Safety of 2 Doses of Remigromig (EYE103) Compared With Ranibizumab (0.5 mg) in Participants With DME

  NCT06571045· Phase 2/3· EyeBiotech Ltd.· Source

Closed trials

• Completed

  A Phase 1b Study to Assess the Safety, Tolerability, Pharmacokinetics, and Exploratory Efficacy of Intravitreal OLN324

  NCT07484074· Phase 1· Ollin Biosciences, Inc.· Source